-
SHC-1 Inhibition Increases CFTR Membrane Abundance in Epithe
2026-06-02
This study reveals that SHC-1 inhibition can enhance plasma membrane localization of the CFTR chloride channel in airway epithelial cells, but with significant cell-type specificity. The findings refine our understanding of CFTR trafficking regulation, with implications for cystic fibrosis and secretory diarrhea research.
-
EPI-001: Advancing Androgen Receptor N-Terminal Domain Inhib
2026-06-01
EPI-001 stands out as a highly selective androgen receptor N-terminal domain inhibitor, enabling robust mechanistic studies in both prostate cancer and AR-driven breast cancer models. This article delivers actionable protocols, experimental enhancements, and troubleshooting strategies to maximize the translational impact of EPI-001 in next-generation oncology research.
-
Bisphenol A Exposure and Abdominal Aortic Aneurysm Mechanism
2026-06-01
This study establishes a mechanistic link between environmental Bisphenol A (BPA) exposure and the development of abdominal aortic aneurysm (AAA), employing integrative modeling and multi-omics validation. Its findings clarify how BPA perturbs vascular cell function and gene expression, advancing risk assessment and suggesting molecular targets for prevention.
-
V5 Epitope Tag Peptide: Redefining Precision in Translationa
2026-05-31
Explore how the V5 Epitope Tag Peptide (GKPIPNPLLGLDST) is transforming protein tagging for translational researchers. This article examines the mechanistic strengths of the V5 tag, recent breakthroughs in antibody screening, and actionable strategies for integrating high-specificity epitope tagging into advanced workflows—bridging evidence from single-molecule microscopy and highlighting the unique reliability of APExBIO’s V5 Epitope Tag Peptide.
-
Rapamycin (Sirolimus): mTOR Inhibition in Macrophage Autopha
2026-05-30
Explore how Rapamycin (Sirolimus) enables precise mTOR pathway control in macrophage autophagy models. This article uniquely bridges immunometabolic signaling, advanced infection research, and practical assay design.
-
Dissecting Aneugen Mechanisms: Insights from 27 Reference Ch
2026-05-29
This study introduces a robust, flow cytometry-based assay to distinguish aneugenic mechanisms in vitro, validated with 27 reference chemicals. The findings offer a reproducible framework for identifying molecular targets of chromosome malsegregation, relevant for cancer biology and toxicological screening.
-
Applied Use of the Alcian Blue & Nuclear Fast Red Staining K
2026-05-29
The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5, from APExBIO, streamlines dual-color histological staining for acid mucopolysaccharides and nuclei, optimizing chondrogenic differentiation assays. Advanced workflow tips and troubleshooting strategies help maximize reproducibility for mucin and mesenchymal stem cell analysis.
-
AG-490 (Tyrphostin B42): Assay Design and JAK2/STAT6 Modulat
2026-05-28
Explore AG-490 (Tyrphostin B42) as a powerful JAK2/EGFR inhibitor for targeting the JAK-STAT signaling pathway. This article uniquely analyzes its role in exosomal SNORD52-mediated macrophage polarization in HCC, guiding optimal assay design for translational cancer research.
-
BCECF-AM: Precision Intracellular pH Sensing Beyond Protocol
2026-05-28
Explore the scientific principles and advanced applications of BCECF-AM, a leading intracellular pH indicator. This in-depth analysis goes beyond standard protocols to reveal how bis(acetoxymethyl) 3,3'-(3',6'-bis(acetoxymethoxy)-5-((acetoxymethoxy)carbonyl)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-2',7'-diyl)dipropanoate empowers transformative research in cell biology.
-
Peripheral RIPK1 and IL-8 as ALS Biomarkers: Primidone Repur
2026-05-27
This study establishes elevated peripheral RIPK1 and IL-8 as robust biomarkers for amyotrophic lateral sclerosis (ALS) and demonstrates that Primidone, long used as an antiepileptic, can significantly reduce these biomarkers in both mouse models and human patients. The findings offer new perspectives on biomarker-driven patient stratification and the repurposing of Primidone for ALS intervention.
-
Saracatinib (AZD0530): Precision Src/Abl Inhibition in Cance
2026-05-27
Saracatinib (AZD0530) delivers robust, selective Src and Abl kinase inhibition, empowering researchers to dissect oncogenic signaling and cell migration with unparalleled reproducibility. Discover protocol refinements, troubleshooting tips, and novel translational insights—directly informed by cutting-edge synaptic signaling research—for advanced cancer biology and neuroscience applications.
-
SIRT1/2 Inhibitor IV (Cambinol): Next-Gen Insights for Metab
2026-05-26
Discover how SIRT1/2 Inhibitor IV (cambinol) enables advanced exploration of metabolic and CNS pathways, including SIRT1-regulated lactylation and tumor suppression. This in-depth analysis reveals new experimental strategies and practical assay guidance for researchers.
-
Deferasirox in Cancer Research: Iron Chelation, Ferroptosis,
2026-05-26
Explore how Deferasirox, an oral iron chelator, is transforming translational oncology by targeting iron metabolism and overcoming ferroptosis resistance in tumors. This article bridges mechanistic insights with actionable strategies for researchers, referencing new findings on the METTL16-SENP3-LTF axis and highlighting APExBIO's role in advancing experimental workflows.
-
FK866 (APO866): NAMPT Inhibition for Cancer Metabolism Resea
2026-05-25
FK866 (APO866) is a potent, non-competitive NAMPT inhibitor used in cancer and vascular aging research. It selectively depletes intracellular NAD, triggering caspase-independent cell death in malignant cells while sparing normal progenitors. Robust in vitro and in vivo data support its application in acute myeloid leukemia (AML) research and mechanistic studies of NAD metabolism.
-
Distinct Volatile Mechanisms of Chuanxiong Cortex and Pith i
2026-05-25
This study uses advanced SPME-GC×GC-MS and network pharmacology to reveal how the cortex and pith of Ligusticum chuanxiong differ in volatile composition and mechanistic pathways for coronary heart disease (CHD) intervention. The findings clarify the specific bioactive molecules, including 1-Phenyl-1-pentanol (Fenipentol), and their target pathways, informing new directions for gastrointestinal and cardiovascular research.